• 1
    Aronson J. Balancing benefits and harms in health care. BMJ 2004;329:30.
  • 2
    Cross JT, Garrison LP. Challenges and opportunities for improving benefit-risk assessment of pharmaceuticals from an economic perspective. Office of Health Economics 2008. Available from:[Accessed May 27, 2010.
  • 3
    Mussen F, Salek S, Walker S. Benefit-Risk Appraisal of Medicines. Oxford: Wiley-Blackwell, 2009.
  • 4
    Briggs AH, Levy AR. Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven? Pharmacoeconomics 2006;24:107986.
  • 5
    Lynd LD, O’Brien BJ. Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis. J Clin Epidemiol 2004;57:795803.
  • 6
    Garrison LP Jr, Towse A, Bresnahan BW. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Aff (Millwood) 2007;26:68495.
  • 7
    Lynd LD. Using incremental net benefit for quantitative benefit-risk analysis case studies of Vioxx® and Lotronex®. Presented at the Benefit-Risk Assessments for Drugs Workshop. Office of Health Economics. October 24, 2007.
  • 8
    Lynd LD, Najafzadeh M, Colley L, et al. Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making—a case study of alosetron in irritable bowel syndrome. Value Health 2009;[Epub ahead of print.
  • 9
    Johnson R, Özdemir S, Hauber B, Kauf TL. Women's willingness to accept perceived risks for vasomotor symptom relief. J Womens Health 2007;16:102840.
  • 10
    Culyer AJ. Deliberative processes. Office of Health Economics 2009.